Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation
Open accessThe DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
Human BCL-2-associated death promoter (hBAD) is an apoptosis-regulatory protein mediating survival signals to carcinoma cells upon phosphorylation of Ser99, among other residues. Herein, we screened multiple small-molecule databases queried in a Laplacian-modified naive Bayesian-based cheminformatics platform and identified a Petasis reaction product as a site-specific inhibitor for hBAD phosphorylation. Based on apoptotic efficacy against mammary carcinoma cells, N -cyclopentyl-3-((4-(2,3-dichlorophenyl) piperazin-1-yl) (2-hydroxyphenyl) methyl) benzamide (NPB) was identified as a potential lead compound. In vitro biochemical analyses demonstrated that NPB inhibited the phosphorylation of hBAD specifically on Ser99. NPB was observed to exert this effect independently of AKT and other kinase activities despite the demonstration of AKT-mediated BAD-Ser99 phosphorylation. Using a structure-based bioinformatics platform, we observed that NPB exhibited predicted interactions with hBAD in silico and verified the same by direct binding kinetics. NPB reduced phosphorylation of BAD-Ser99 and enhanced caspase 3/7 activity with associated loss of cell viability in various human cancer cell lines derived from mammary, endometrial, ovarian, hepatocellular, colon, prostatic, and pancreatic carcinoma. Furthermore, by use of a xenograft model, it was observed that NPB, as a single agent, markedly diminished BAD phosphorylation in tumor tissue and significantly inhibited tumor growth. Simila…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A small molecule (NPB) that inhibits BAD phosphorylation at S99, independent of kinase activity, and promotes apoptosis of cancer cells has been recently described [15].”
From Combining Mitomycin C with inhibition of BAD phosphorylation enhances apoptotic cell death in advanced cervical cancer (2024) · cites this paper as [15]
In the citing paper
“Hence, as a core effector of both pathways, inhibition of the actions of phosphorylated BAD in cancer cells (herein with Ser99 mutated BAD or NPB) decreases cancer cell survival by promoting intrinsic apoptosis [15]; and more so in the presence of cytotoxic agents.”
From Combining Mitomycin C with inhibition of BAD phosphorylation enhances apoptotic cell death in advanced cervical cancer (2024) · cites this paper as [15]
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197 · cited 1×
“Given the current interest in cancer cell dependence on glucose (61), it is noteworthy that glucose deprivation results in BAD dephosphorylation and BAD-mediated apoptosis (58).”
BackgroundChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382 · cited 3×
“The hBAD protein target was normalized by comparing the predicted targets in the dataset used in this study with target predictions of a background dataset comprising 3,000 compounds in total from PubChem, GDB13, and ChEMBL; a probability of 0.05 or higher was considered “as predicted” in this case.”
MethodInfluentialCellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216 · cited 2×
“Compounds targeting BAD, such as NPB, would be useful in solid tumors regardless of whether a tumor was predominantly dependent on BCL-2 or BCL-xL, because both BCL-2 and BCL-xL are BAD dimerization partners (23, 43).”
BackgroundZINC − A Free Database of Commercially Available Compounds for Virtual Screening
Irwin, J. J., & Shoichet, B. K. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049714+ · Cited by 4,058
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960 · cited 1×
“We docked the series of compounds to the exposed Bcl-2/BAD protein–protein interface known to bind small molecules (68).”
BackgroundLetai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · cited 1×
“BCL-xL is critical for determining platelet lifespan (57).”
BackgroundSchneider, G. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.232 · Cited by 910 · cited 1×
“7 million compounds for predicted interaction with BAD using a unique in silico mapping of chemical space in the drug-discovery area (13).”
MethodMechanisms of Action of Bcl-2 Family Proteins
Shamas-Din, A., Kale, J., Leber, B., & Andrews, D. W. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008714 · Cited by 705
BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis
Danial, N. N., Gramm, C. F., Scorrano, L., Zhang, C.-Y., Krauss, S., Ranger, A. M., Robert Datta, S., Greenberg, M. E., Licklider, L. J., Lowell, B. B., et al. (2003) · Nature · doi:10.1038/nature01825 · Cited by 705 · cited 2×
“Mice deficient for BAD or expressing the triple serine mutation described above also display fasting hyperglycemia (58).”
BackgroundPhosphorylation and Inactivation of BAD by Mitochondria-Anchored Protein Kinase A
Harada, H., Becknell, B., Wilm, M., Mann, M., Huang, L. J.-S., Taylor, S. S., Scott, J. D., & Korsmeyer, S. J. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80469-4 · Cited by 645
p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD
Harada, H., Andersen, J. S., Mann, M., Terada, N., & Korsmeyer, S. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171301998 · Cited by 549
A New and Practical Synthesis of α-Amino Acids from Alkenyl Boronic Acids
Petasis, N. A., & Zavialov, I. A. (1997) · Journal of the American Chemical Society · doi:10.1021/ja963178n · Cited by 444 · cited 2×
“The Petasis reaction is a three-component boronic Mannich-type reaction that contributes significantly to the advancement of organic transformations by providing greater flexibility, novelty, and efficiency (16).”
BackgroundMethodPETROS, A. M., NETTESHEIM, D. G., WANG, Y., OLEJNICZAK, E. T., MEADOWS, R. P., MACK, J., SWIFT, K., MATAYOSHI, E. D., ZHANG, H., THOMPSON, C. B., et al. (2000) · Protein Science · doi:10.1017/s096183680000331x · Cited by 412 · cited 1×
“(i) Modeled complex of Bcl-2 (green cartoon) and a 25-residue helical fragment of BAD (blue cartoon) based on the structures of Protein Data Bank ID code 2O22 and 1G5J (70, 74).”
Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL
Bruncko, M., Oost, T. K., Belli, B. A., Ding, H., Joseph, M. K., Kunzer, A., Martineau, D., McClellan, W. J., Mitten, M., Ng, S.-C., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061152t · Cited by 304
Survival Factor-Mediated BAD Phosphorylation Raises the Mitochondrial Threshold for Apoptosis
Datta, S. R., Ranger, A. M., Lin, M. Z., Sturgill, J. F., Ma, Y.-C., Cowan, C. W., Dikkes, P., Korsmeyer, S. J., & Greenberg, M. E. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00326-x · Cited by 282
Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Vaillant, F., Merino, D., Lee, L., Breslin, K., Pal, B., Ritchie, M. E., Smyth, G. K., Christie, M., Phillipson, L. J., Burns, C. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.002 · Cited by 276 · cited 5×
“Deng J, Letai A (2013) Priming BCL-2 to kill: The combination therapy of tamoxifen and ABT-199 in ER+ breast cancer.”
BackgroundInfluentialHayakawa, J., Ohmichi, M., Kurachi, H., Kanda, Y., Hisamoto, K., Nishio, Y., Adachi, K., Tasaka, K., Kanzaki, T., & Murata, Y. (2000) · PubMed · Cited by 274
Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway
Fang, X., Yu, S., Eder, A., Mao, M., Bast, R. C., Boyd, D., & Mills, G. B. (1999) · Oncogene · doi:10.1038/sj.onc.1203076 · Cited by 266 · cited 2×
“Phosphorylation of BAD at either of these residues results in the loss of the ability of hBAD to heterodimerize with BCL-xL or BCL-2 (4).”
BackgroundBad -deficient mice develop diffuse large B cell lymphoma
Ranger, A. M., Zha, J., Harada, H., Datta, S. R., Danial, N. N., Gilmore, A. P., Kutok, J. L., Le Beau, M. M., Greenberg, M. E., & Korsmeyer, S. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533446100 · Cited by 263 · cited 1×
“However, BAD gene-deleted mice mature to adulthood and are largely indistinguishable from control mice, except that their seminiferous tubules demonstrated prominent multinucleated giant cells (33) and ∼20% developed B cell lymphoma at 18 mo.”
BackgroundMacdonald, A., Campbell, D. G., Toth, R., McLauchlan, H., Hastie, C. J., & Arthur, J. S. C. (2006) · BMC Cell Biology · doi:10.1186/1471-2121-7-1 · Cited by 246 · cited 1×
“Both serine residues are also phosphorylated by Pim family kinases and function to prevent apoptosis (3).”
BackgroundGilmore, A. P., Valentijn, A. J., Wang, P., Ranger, A. M., Bundred, N., O'Hare, M. J., Wakeling, A., Korsmeyer, S. J., & Streuli, C. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108863200 · Cited by 207
Activation of PI3K/Akt signaling and hormone resistance in breast cancer
Tokunaga, E., Kimura, Y., Mashino, K., Oki, E., Kataoka, A., Ohno, S., Morita, M., Kakeji, Y., Baba, H., & Maehara, Y. (2006) · Breast Cancer · doi:10.2325/jbcs.13.137 · Cited by 199 · cited 1×
“Aberrant activation of AKT is positively associated with a poor prognosis in carcinomas and with resistance to endocrine therapy and chemotherapy in MC (39).”
BackgroundSensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Oakes, S. R., Vaillant, F., Lim, E., Lee, L., Breslin, K., Feleppa, F., Deb, S., Ritchie, M. E., Takano, E., Ward, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104778108 · Cited by 193 · cited 7×
“Deng J, Letai A (2013) Priming BCL-2 to kill: The combination therapy of tamoxifen and ABT-199 in ER+ breast cancer.”
BackgroundInfluentialCorrelation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.
Kanamori, Y., Kigawa, J., Itamochi, H., Shimada, M., Takahashi, M., Kamazawa, S., Sato, S., Akeshima, R., & Terakawa, N. (2001) · PubMed · Cited by 181
14-3-3 Inhibits Bad-Induced Cell Death through Interaction with Serine-136
Masters, S. C., Yang, H., Datta, S. R., Greenberg, M. E., & Fu, H. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.6.1325 · Cited by 169 · cited 2×
“Phosphorylated BAD protein is heterodimerized with the 14-33 protein and is sequestered in the cytoplasm (5).”
BackgroundLi, C., Zhang, G., Zhao, L., Ma, Z., & Chen, H. (2015) · World Journal of Surgical Oncology · doi:10.1186/s12957-016-0769-9 · Cited by 167 · cited 1×
“This association can be reversed by dephosphorylation of BAD, following which it can dimerize with BCL-2, BCL-xL, or BCL-w, which allows activation of BAK/BAX and promotes the release of cytochrome C to the cytoplasm with the subsequent promotion of the intrinsic apoptotic pathway (6, 7).”
BackgroundMohan, C. D., Bharathkumar, H., Bulusu, K. C., Pandey, V., Rangappa, S., Fuchs, J. E., Shanmugam, M. K., Dai, X., Li, F., Deivasigamani, A., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.601104 · Cited by 159 · cited 2×
“These observations were found to be in concordance with other known BCL-2 inhibitors (18).”
MethodResultSelf-citationJiang, P., Du, W., Heese, K., & Wu, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01025-06 · Cited by 157 · cited 2×
“Independent of its phosphorylation status, BAD also interacts with TP53 and forms a BAD/TP53 complex at mitochondria to induce apoptosis (8).”
BackgroundSchmelzle, T., Mailleux, A. A., Overholtzer, M., Carroll, J. S., Solimini, N. L., Lightcap, E. S., Veiby, O. P., & Brugge, J. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700115104 · Cited by 145
Fernando, R. I., & Wimalasena, J. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-11-0823 · Cited by 139 · cited 1×
“Multiple reports have demonstrated the persistent activation of AKT in carcinomas with resultant phosphorylation of BAD at Ser99 to promote cell survival (29, 35).”
BackgroundBRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Perna, D., Karreth, F. A., Rust, A. G., Perez-Mancera, P. A., Rashid, M., Iorio, F., Alifrangis, C., Arends, M. J., Bosenberg, M. W., Bollag, G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418163112 · Cited by 135 · cited 1×
“Furthermore, BAD phosphorylation is critically associated with acquired resistance to chemotherapeutic agents such as vemurafenib in melanoma (12) and other inhibitors of the RAS/MAP kinase and PI3K/AKT/ mTOR pathways (9).”
BackgroundSharma, N., Thomas, S., Golden, E. B., Hofman, F. M., Chen, T. C., Petasis, N. A., Schönthal, A. H., & Louie, S. G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.07.029 · Cited by 129 · cited 1×
“An antimalarial agent, Mefloquine, was previously generated using the Petasis reaction and is known to inhibit autophagy and induce cell death of various mammary carcinoma (MC) cells (17).”
BackgroundNovick, P. A., Ortiz, O. F., Poelman, J., Abdulhay, A. Y., & Pande, V. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079568 · Cited by 129 · cited 2×
“The structures of small molecules used in the study were retrieved from ZINC (14) and from traditional Chinese and Ayurvedic medicinal compound databases (15).”
MethodMa, Y., Qin, H., & Cui, Y. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.11.010 · Cited by 119 · cited 1×
“Multiple reports have demonstrated the persistent activation of AKT in carcinomas with resultant phosphorylation of BAD at Ser99 to promote cell survival (29, 35).”
BackgroundTargeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Yu, Y., Savage, R. E., Eathiraj, S., Meade, J., Wick, M. J., Hall, T., Abbadessa, G., & Schwartz, B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140479 · Cited by 118 · cited 1×
“AKT inhibitors such as ARQ092 (59) also raise blood glucose levels clinically (which is successfully treated with metformin), as is consistent with AKTdependent phosphorylation of BAD (60).”
BackgroundTargeting BCL2-Proteins for the Treatment of Solid Tumours
Vogler, M. (2014) · Advances in Medicine · doi:10.1155/2014/943648 · Cited by 117 · cited 5×
“One explanation is that BCL-xL expression is increased more often than BCL-2 expression in solid tumors (43).”
BackgroundInfluentialDecreased mitochondrial priming determines chemoresistance of colon cancer stem cells
Colak, S., Zimberlin, C. D., Fessler, E., Hogdal, L., Prasetyanti, P. R., Grandela, C. M., Letai, A., & Medema, J. P. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.37 · Cited by 114
Mutant B-RAF mediates resistance to anoikis via Bad and Bim
Boisvert-Adamo, K., & Aplin, A. E. (2008) · Oncogene · doi:10.1038/sj.onc.1211003 · Cited by 102
BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival
Marchion, D. C., Cottrill, H. M., Xiong, Y., Chen, N., Bicaku, E., Fulp, W. J., Bansal, N., Chon, H. S., Stickles, X. B., Kamath, S. G., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0735 · Cited by 100 · cited 2×
“Such examples would include ovarian cancer, in which BAD phosphorylation has been positively associated with dismal survival outcomes (10).”
BackgroundBH 3‐only proteins: a 20‐year stock‐take
Doerflinger, M., Glab, J. A., & Puthalakath, H. (2015) · The FEBS Journal · doi:10.1111/febs.13190 · Cited by 87 · cited 3×
“T BCL-2–associated death promoter (BAD) plays a pivotal role in regulating apoptosis by interacting with BCL-2, BCLxL, and BCL-w (1).”
BackgroundInfluentialA kinase-independent function of AKT promotes cancer cell survival
Vivanco, I., Chen, Z. C., Tanos, B., Oldrini, B., Hsieh, W.-Y., Yannuzzi, N., Campos, C., & Mellinghoff, I. K. (2014) · eLife · doi:10.7554/elife.03751 · Cited by 87 · cited 1×
“demonstrated that AKT inhibitors also decrease the phosphorylation of BAD at Ser99, and numerous AKT inhibitors, including ARQ 092, AZD5363, GSK690693, GDC-0068, and MK-2206, have been advanced to clinical trial and have shown encouraging results (40, 41).”
BackgroundBad phosphorylation as a target of inhibition in oncology
Bui, N.-L.-C., Pandey, V., Zhu, T., Ma, L., Basappa, & Lobie, P. E. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.017 · Cited by 86 · cited 4×
“Furthermore, BAD phosphorylation is critically associated with acquired resistance to chemotherapeutic agents such as vemurafenib in melanoma (12) and other inhibitors of the RAS/MAP kinase and PI3K/AKT/ mTOR pathways (9).”
BackgroundInfluentialSelf-citationRosenquist, M. (2003) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2003000400001 · Cited by 83 · cited 1×
“Furthermore, BAD appears to exert BCL-2 protein-independent functions by interacting with 14-3-3 (5, 47), by modulating apoptosis in a complex with p53 (8), by mediating PAK1- and RAF (including BRAF-V600E)-stimulated proliferation and survival (48, 49) and cytokine-stimulated proliferation mediated by CaMKII-γ (50).”
BackgroundTamaki, H., Harashima, N., Hiraki, M., Arichi, N., Nishimura, N., Shiina, H., Naora, K., & Harada, M. (2014) · Oncotarget · doi:10.18632/oncotarget.2550 · Cited by 80 · cited 1×
“NPB could be useful in all situations in which BCL2 protein inhibitors are used in combination with other therapeutics, including tamoxifen treatment of breast cancer and treatment of other cancers with cytotoxic agents such as docetaxel (55).”
Gu, Z., Wu, J., Wang, S., Suburu, J., Chen, H., Thomas, M. J., Shi, L., Edwards, I. J., Berquin, I. M., & Chen, Y. Q. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt147 · Cited by 75
Pandey, V., Wu, Z., Zhang, M., Li, R., Zhang, J., Zhu, T., & Lobie, P. E. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0429-3 · Cited by 73 · cited 2×
“WB analysis was performed as previously described (18, 64) using the following antibodies: rabbit anti-pBAD (Ser112), goat antipBAD (Ser136), mouse anti-BAD, mouse anti-BAK, mouse anti-BAX, mouse anti–BCL-2, mouse anti–BCL-XL, mouse anti-CDKN1A, mouse anti-CDK2, rabbit anti-CDK4, mouse anti-CYCS, and mouse anti-TP53 f…”
MethodSelf-citationSalas, T. R., Reddy, S. A., Clifford, J. L., Davis, R. J., Kikuchi, A., Lippman, S. M., & Menter, D. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302972200 · Cited by 70 · cited 1×
“Specifically, the phosphorylation of the direct AKT substrate [GSK-3 α/β (S21/S9)] (19) was not affected by NPB treatment, despite NPB inhibition of hBAD phosphorylation at Ser99 in the same cell extract (SI Appendix, Supporting Information 4B).”
BackgroundInfluenza Virus Induces Apoptosis via BAD-Mediated Mitochondrial Dysregulation
Tran, A., Cortens, J. P., Du, Q., Wilkins, J. A., & Coombs, K. M. (2012) · Journal of Virology · doi:10.1128/jvi.02017-12 · Cited by 70
Peng, S., Lee, C., Hour, M., Tsai, S., Kuo, D., Chen, F., Shieh, P., & Yang, J. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2175 · Cited by 67
Development of Small-Molecule PUMA Inhibitors for Mitigating Radiation-Induced Cell Death
Mustata, G. I., Li, M., Zevola, N., Bakan, A., Zhang, L., Epperly, M. W., Greenberger, J. S., Yu, J., & Bahar, İ. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611794072641 · Cited by 66 · cited 1×
“However, thus far, the response in solid tumors has been limited (44, 45).”
BackgroundNovel Inhibitors of AKT: Assessment of a Different Approach Targeting the Pleckstrin Homology Domain
Meuillet, E. J. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796011292 · Cited by 62 · cited 1×
“However, high degrees of homology in the ATP-binding domain between AKT, protein kinase A (PKA), and protein kinase C (PKC) and mutations in the AKT gene present possible significant obstacles for the clinical specificity and efficacy of AKT inhibitors (42).”
BackgroundPredicting the mechanism of phospholipidosis
Lowe, R., Mussa, H. Y., Nigsch, F., Glen, R. C., & Mitchell, J. B. O. (2012) · Journal of Cheminformatics · doi:10.1186/1758-2946-4-2 · Cited by 62 · cited 1×
“Initially, we employed the Laplacian-modified naive Bayesian classifier to rank hBAD as the target for the queried compounds (62).”
MethodTargeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cells
Sastry, K. S. R., Al-Muftah, M. A., Li, P., Al-Kowari, M. K., Wang, E., Ismail Chouchane, A., Kizhakayil, D., Kulik, G., Marincola, F. M., Haoudi, A., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.140 · Cited by 56 · cited 2×
“Extensive experimental evidence in the literature clearly demonstrates that neither depletion nor forced expression of BAD (27–29) affects cell viability, whereas forced expression of BAD phosphorylation-deficient mutants (11, 30) results in loss of cell viability.”
BackgroundNovel Adamantanyl-Based Thiadiazolyl Pyrazoles Targeting EGFR in Triple-Negative Breast Cancer
Sebastian, A., Pandey, V., Mohan, C. D., Chia, Y. T., Rangappa, S., Mathai, J., Baburajeev, C. P., Paricharak, S., Mervin, L., Bulusu, K. C., et al. (2016) · ACS Omega · doi:10.1021/acsomega.6b00251 · Cited by 55 · cited 1×
“Phosphatidylserine treatment and cell death were assessed using the Annexin-V-FLUOS Staining Kit (Life Technologies) and propidium iodide (PI)-stained cells as described previously (65, 67).”
MethodSelf-citationYou, M., Chen, Y.-J., Chong, Q.-Y., Wu, M.-M., Pandey, V., Chen, R.-M., Liu, L., Ma, L., Wu, Z., Zhu, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16950 · Cited by 53 · cited 1×
“Histological analysis was performed as previously described (64, 72, 73).”
MethodSelf-citationYe, D. Z., Jin, S., Zhuo, Y., & Field, J. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027637 · Cited by 52
BAD-mediated apoptotic pathway is associated with human cancer development
Stickles, X. B., Marchion, D. C., Biçaku, E., Sawah, E. A., Abbasi, F., Xiong, Y., Zgheib, N. B., Boac, B. M., Orr, B. C., Judson, P. L., et al. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2091 · Cited by 50 · cited 1×
“Also, by the use of clinico-genomic datasets, the BADmediated apoptotic pathway has been reported to be highly significantly associated with the development and progression of breast, ovarian, colon, and endometrial cancers (51).”
BackgroundRapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells
Liu, Y., Sun, S., Owonikoko, T. K., Sica, G., Curran, W. J., Khuri, F. R., & Deng, X. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0578 · Cited by 50
Sulaiman, N. B. S., Mohan, C. D., Basappa, B., Pandey, V., Rangappa, S., Bharathkumar, H., Kumar, A. P., Lobie, P. E., & Rangappa, K. S. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3615 · Cited by 45 · cited 1×
“Phosphatidylserine treatment and cell death were assessed using the Annexin-V-FLUOS Staining Kit (Life Technologies) and propidium iodide (PI)-stained cells as described previously (65, 67).”
MethodSelf-citationSmall Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy
Masood, A., Azmi, A. S., & Mohammad, R. M. (2011) · Cancers · doi:10.3390/cancers3021527 · Cited by 37 · cited 1×
“However, thus far, the response in solid tumors has been limited (44, 45).”
BackgroundThe RhoJ-BAD signaling network: An Achilles’ heel for BRAF mutant melanomas
Ruiz, R., Jahid, S., Harris, M. L., Marzese, D. M., Espitia, F., Vasudeva, P., Chen, C., de Feraudy, S. M., Wu, J., Gillen, D. L., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006913 · Cited by 28 · cited 1×
“Extensive experimental evidence in the literature clearly demonstrates that neither depletion nor forced expression of BAD (27–29) affects cell viability, whereas forced expression of BAD phosphorylation-deficient mutants (11, 30) results in loss of cell viability.”
BackgroundPIM2 Kinase Is Induced by Cisplatin in Ovarian Cancer Cells and Limits Drug Efficacy
Musiani, D., Hammond, D. E., Cirillo, L., Erriquez, J., Olivero, M., Clague, M. J., & Renzo, M. F. D. (2014) · Journal of Proteome Research · doi:10.1021/pr500651n · Cited by 27 · cited 1×
“Specific chemotherapeutics such as cisplatin have also been reported to stimulate BAD phosphorylation via PIM kinases, promoting cisplatin resistance (56), and NPB could prove useful as a combination therapy to improve therapeutic outcome.”
BackgroundWang, X.-N., Wang, S., Pandey, V., Chen, P., Li, Q., Wu, Z., Wu, Q., & Lobie, P. E. (2015) · Medicine · doi:10.1097/md.0000000000000860 · Cited by 27 · cited 1×
“Histological analysis was performed as previously described (64, 72, 73).”
MethodSelf-citationAkl, H., Badran, B. M., Zein, N. E., Bex, F., Sotiriou, C., Willard-Gallo, K. E., Burny, A., & Martiat, P. (2007) · Leukemia · doi:10.1038/sj.leu.2404585 · Cited by 22
BAD Contributes to RAF-mediated Proliferation and Cooperates with B-RAF-V600E in Cancer Signaling
Polzien, L., Baljuls, A., Albrecht, M., Hekman, M., & Rapp, U. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.177345 · Cited by 20
Pandey, V., Zhang, M., Chong, Q.-Y., You, M., Raquib, A. R., Pandey, A. K., Liu, D., Liu, L., Ma, L., Jha, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20461 · Cited by 20
Self-citationDecoyFinder, a tool for finding decoy molecules
Cereto‐Massagué, A., García-Vallvé, S., & Pujadas, G. (2012) · Journal of Cheminformatics · doi:10.1186/1758-2946-4-s1-p2 · Cited by 17
Hojabrpour, P., Waissbluth, I., Ghaffari, M., Cox, M., & Duronio, V. (2012) · Biochemical Journal · doi:10.1042/bj20111256 · Cited by 15 · cited 2×
“Hojabrpour P, Waissbluth I, Ghaffari M, Cox ME, Duronio V (2012) CaMKII-γ mediates phosphorylation of BAD at Ser170 to regulate cytokine-dependent survival and proliferation.”
BackgroundSeow, H. F., Yip, W. K., Loh, H. W., Ithnin, H., Por, P., & Rohaizak, M. (2009) · Pathology & Oncology Research · doi:10.1007/s12253-009-9216-3 · Cited by 14
Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer
Deng, J., & Letai, A. G. (2013) · Breast Cancer Research · doi:10.1186/bcr3568 · Cited by 11 · cited 1×
“The paucity of single-agent efficacy of BCL-2 protein inhibitors such as ABT-737 or ABT-199 (52, 53) in solid tumors has prompted the examination of these compounds in combination therapy (54).”
BackgroundSaleh, M. N., Papadopoulos, K. P., Arabnia, A., Patnaik, A., Stein, R. M., Cattaneo, F., Abbadessa, G., Greenberg, J., Warren, S., & Tolcher, A. W. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-197 · Cited by 4
AKT Inhibitors Take Steps Forward
(2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2013-053 · Cited by 1
Research works printed but not linked: 2
- 10.1021/ci049714 · DOI
- 10.1110/ps.9.12.2528 · doi:10.1110/ps.9.12.2528 · Paper page
Cited by
Reactivity and Synthetic Applications of Multicomponent Petasis Reactions
Wu, P., Givskov, M., & Nielsen, T. E. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00214 · Cited by 315
Post-translational modifications of Beclin 1 provide multiple strategies for autophagy regulation
Hill, S. M., Wrobel, L., & Rubinsztein, D. C. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0254-9 · Cited by 216
Lee, J. H., Mohan, C. D., Deivasigamani, A., Jung, Y. Y., Rangappa, S., Basappa, B., Chinnathambi, A., Alahmadi, T. A., Alharbi, S. A., Garg, M., et al. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.07.004 · Cited by 144
“Immunocytochemistry was carried out as per the prior reported protocol [50].”
MethodSelf-citationEscaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds
Jadimurthy, R., Mayegowda, S. B., Nayak, S. C., Mohan, C. D., & Rangappa, K. S. (2022) · Biotechnology Reports · doi:10.1016/j.btre.2022.e00728 · Cited by 116
Self-citationBrusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma
Lee, J. H., Rangappa, S., Mohan, C. D., Basappa, B., Sethi, G., Lin, Z., Rangappa, K. S., & Ahn, K. S. (2019) · Biomolecules · doi:10.3390/biom9100550 · Cited by 81
Self-citation
Metadata
- Authors
- Pandey, V., Wang, B., Mohan, C. D., Raquib, A. R., Rangappa, S., Srinivasa, V., Fuchs, J. E., Girish, K. S., Zhu, T., Bender, A., Ma, L., Yin, Z., Basappa, Rangappa, K. S., & Lobie, P. E.
- Affiliations
- Tsinghua–Berkeley Shenzhen Institute (CN)
- Jinan University (CN)
- University of Mysore (IN)
- National University of Singapore (SG)
- Adichunchanagiri Institute for Molecular Medicine, BG Nagara, 571448 Karnataka, India;
- Bangalore University (IN)
- University of Cambridge (GB)
- Tumkur University (IN)
- University of Science and Technology of China (CN)
- Laboratory of Chemical Biology, Department of Chemistry, Bangalore University, 560001 Bangalore, India;
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2018-10-11
- Volume
- 115
- Issue
- 44
- Pages
- E10505-E10514
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6217419
- OpenAlex
- W2896536135
- Cited by
- 59
- References
- 75
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 5 · 2023: 8 · 2022: 8 · 2021: 10 · 2020: 8 · 2019: 9 · 2018: 1
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- MyPrints@UOM (Mysore University Library) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- Bad phosphorylation, small molecule inhibitors, NPB, caspase-3/7 activation, apoptosis, cancer cell lines, xenograft tumor growth, structure-based drug design, anticancer agents
- MeSH terms
- Antineoplastic Agents, Benzamides, Cell Survival, Humans, Phosphorylation, Piperazines, Serine, Databases, Factual, Drug Delivery Systems, Apoptosis, Surface Plasmon Resonance, RNA Interference, Cell Proliferation, bcl-Associated Death Protein, Small Molecule Libraries, Drug Discovery, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.